ARTA / Prenetics Sets Merger Vote

by | Apr 11, 2022

Vote date set for Hong-Kong based COVID-19 lab provider Prenetics. A look at upcoming merger and extension votes. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

Artisan Acquisition Corp. (ARTA) Sets Vote Date for Merger with Prenetics

Artisan Acquisition Corp. (ARTA) sets May-9 for vote on its merger with Hong Kong-based Prenetics (PRE). Prenetics is focused on genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and colorectal cancer screening. The transaction values Prenetics at an enterprise value of $1.25B with a combined equity value of approximately $1.7B.

Vickers Vantage Corporation I (VCKA) Extends

Vickers Vantage Corporation I (VCKA) extends to July-11 and adds $0.075 to trust. VCKA has a DA with biopharma Scilex Holding Company, a subsidiary of Sorrento Therapeutics (SRNE).  The SPAC is led by Jeffrey Chi, Chairman and Chief Executive Officer, Chris Ho, Chief Financial Officer and Director, and Special Advisor Dr. Finian Tan.

Elsewhere in SPACs

  • Satellite communications technology specialist SatixFy announced the passing of Yoel Gat, CEO of the company. SatixFy has DA with Endurance Acquisition Corp. (EDNC), which was announced in March)

Upcoming Merger and Extension Votes

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.